Third Harmonic Bio Inc

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fate Therapeutics

Graphite Bio

Century Therapeutics

Vera Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

Long-term investors of Third Harmonic Bio (NASDAQ: THRD ) are feeling some discomfort today, to put it mildly. This morning, THRD stock is losing the majority of its value because the company halted a clinical trial.

Why Is Third Harmonic Bio (THRD) Stock Down 75% Today?

Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common inflammatory skin condition, over safety concerns. Third Harmonic said it plans to provide the full data from the study as well as an update on its corporate strategy in early 2023.

Third Harmonic's stock falls 75% after discontinuing clinical trial

-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID

Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria

CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, November 29, 2022, from 10:05-10:25 a.m. ET.

Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference

Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025

Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update

A partner in a large Cambridge, Massachusetts-based venture capital firm is confident that investors' appetite for biotech startups will begin to pick up in the fall.

Third Harmonic Scores Most Successful Biotech IPO in Months

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, today announced the closing of its initial public offering of 12,535,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,635,000 additional shares of common stock, at a public offering price of $17.00 per share. All of the shares were offered by Third Harmonic Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Third Harmonic Bio, were approximately $213.1 million. The shares began trading on the Nasdaq Global Market on September 15, 2022 under the ticker symbol “THRD.”

Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

One of the hottest recent biotech initial public offerings belongs to Third Harmonic (NASDAQ: THRD ). Today, this early stage biotech company focused on developing a drug for allergic and inflammatory diseases went public.

Is Third Harmonic Bio (THRD) Stock the Next Red-Hot IPO?

Third Harmonic Bio Inc. THRD, +22.50% received a warm Wall Street welcome Thursday, as the biotechnology company's stock opened 20.6% above the initial public offering price. The company, which specializes in allergic and inflammatory diseases, said early Thursday that its IPO priced at $17 a share, in the middle of the expected range, as the company raised $185.3 million.

Third Harmonic Bio stock opens more than 20% above IPO price

Third Harmonic Bio Inc. THRD, -58.40% , a biotech specializing in allergic and inflammatory diseases, priced its initial public offering late Wednesday at $17 a share the midpoint of its $16 to $18 price range. But the company was able to upsize the deal to 10.9 million shares from an earlier plan to offer just 9 million.

Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range

CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, today announced the pricing of its upsized initial public offering of 10,900,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by Third Harmonic Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Third Harmonic Bio, are expected to be $185.3 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2022 under the ticker symbol “THRD.” The offering is expected to close on September 19, 2022, subject to the satisfaction of customary closing conditions. In addition, Third Harmonic Bio has granted the underwriters a 30-day option to purchase up to an additional 1,635,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering

News for Third Harmonic Bio Inc Stock (THRD)